Pleuromutilin hippuric acid ester with antibacterial activity and a method of preparing the same

US11117859B1 · US · B1

Patent metadata
FieldValue
Publication numberUS-11117859-B1
Application numberUS-202117175575-A
CountryUS
Kind codeB1
Filing dateFeb 12, 2021
Priority dateFeb 12, 2021
Publication dateSep 14, 2021
Grant dateSep 14, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A compound with anti-drug resistant bacteria activity having the following formula (I) is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound having the following formula (I): 2. A method of preparing the compound of formula (I) of claim 1 , comprising: reacting a compound of formula (II) with a compound of formula (III) to obtain the compound of formula (I): 3. The method of claim 2 , wherein the reaction of the compound of formula (II) with the compound of formula (III) comprises the following steps: placing the compound of formula (II) and the compound of formula (III), in a molar ratio of 1:1 to 1:1.3, in a reactor; adding an organic solvent and a catalytic amount of 4-dimethylaminopyridine (4-DMAP) under nitrogen atmosphere to obtain a reaction mixture; stirring the reaction mixture at 0° C. for five minutes and then adding N,N′-dicyclohexylcarbodiimide (DCC) to the reaction mixture; reacting the reaction mixture at 25-70° C. for 3 to 7 hours; concentrating the reaction mixture and extracting with ethyl acetate to obtain a crude product; and purifying the crude product on a silica gel fresh chromatography column with petroleum ether and ethyl acetate with a ratio of 1:1 to 4:1 as an eluent to obtain the compound of formula (I). 4. The method of claim 3 , the organic solvent is toluene, 1,2-dichloroethane, or dimethylformamide (DMF). 5. The method of claim 4 , wherein the organic solvent is 1,2-dichloroethane. 6. The method of claim 3 , wherein the molar ratio of the compound of formula (II) and the compound of formula (III) is 1:1.1. 7. The method of claim 3 , wherein the reaction mixture is heated at 60° C. 8. The method of claim 3 , wherein the reaction mixture is reacted for 5 hours. 9. The method of claim 3 , wherein the eluent is petroleum ether:ethyl acetate=3:1. 10. The method of claim 2 , wherein the reaction of the compound of formula (II) with the compound of formula (III) comprises the following steps: placing the compound of formula (II), a catalyst, and an ionic liquid in a reactor under nitrogen atmosphere, the catalyst being 12-molybdosilicic acid hydrate (H 6 Mo 12 O 41 Si); adding the compound of formula (III) to the reactor to form a reaction mixture; heating the reaction mixture at 20-60° C. for 4-8 hours; placing the reaction mixture in a separating funnel to separate a crude product; purifying the crude product by recrystallization in methanol to obtain the compound of formula (I); and recycling the ionic liquid. 11. The method of claim 10 , wherein the ionic liquid is 1-octyl-3-methylimidazolium hexafluorophosphate (C 12 H 23 F 6 N 2 P),1-hexyl-3-methylimidazolium tetrafluoroborate or 1-butyl-3-methylimidazolium tetrafluoroborate. 12. The method of claim 11 , wherein the ionic liquid is the ionic liquid is 1-octyl-3-methylimidazolium hexafluorophosphate. 13. The method of claim 10 , wherein the compound of formula (II) and the compound (III) have a molar ratio of 1:1 to 1:1.3. 14. The method of claim 13 , wherein the molar ratio of the compound of formula (II) and the compound of formula (III) is 1:1.1. 15. The method of claim 10 , wherein the reaction mixture is heated at 30° C. 16. The method of claim 10 , wherein the reaction mixture is heated for 6 hours.

Assignees

Inventors

Classifications

  • having three condensed rings with in total fourteen carbon atoms and having a having a [5.4.3.0(1,8)] ring structure, e.g. pleuromutiline · CPC title

  • C07C233/83Primary

    of an acyclic saturated carbon skeleton · CPC title

  • Optical isomers · CPC title

  • Separation; Purification · CPC title

  • by reactions not involving the formation of carboxamide groups · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11117859B1 cover?
A compound with anti-drug resistant bacteria activity having the following formula (I) is disclosed. The methods of preparing the compound of formula (I) are also disclosed.
Who is the assignee on this patent?
Yang Dan, Li Jingyi, Xin Liang, and 11 more
What technology area does this patent fall under?
Primary CPC classification C07C233/83. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).